Login
$CRSP
$40.61 +$0.24 (0.59%) After hours

$CRSP 8-K SEC Filings

Filed On Filing
02 Nov 2026 8-K: Results of Operations and Financial Condition

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 –

19 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Employment Agreement (“Agreement”) is made as of the Nineteenth (19th) day of October, 2026 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew J. Silver (the “Executive” and, together with the Comp...

03 Aug 2026 8-K: Results of Operations and Financial Condition

ZUG, Switzerland and BOSTON, August 3, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.

04 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

(Translation; in case of controversy the German text shall prevail)

04 May 2026 8-K: Results of Operations and Financial Condition

ZUG, Switzerland and BOSTON, May 4, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.

16 Mar 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CRISPR THERAPEUTICS AGANDU.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION,as TrusteeINDENTUREDated as of March 16, 2026

11 Mar 2026 8-K: Other Events

ZUG, Switzerland and BOSTON, March 11, 2026 – CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a privat...

12 Feb 2026 8-K: Results of Operations and Financial Condition

ZUG, Switzerland and BOSTON, February 12, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

12 Jan 2026 8-K: Other Events

On January 12, 2026, CRISPR Therapeutics AG (the “Company”) issued a press release highlighting, among other things, selected updates related to its wholly-owned cardiovascular, autoimmune, immuno-oncology and regenerative medicine progr...

10 Nov 2025 8-K: Results of Operations and Financial Condition

-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine-

15 Oct 2025 8-K: Other Events

We have acted as Swiss counsel to CRISPR Therapeutics AG, Zug, Switzerland (the Company) on matters of Swiss law in connection with the Company’s filing of a registration statement on Form S-3 automatic shelf registration (as amended or ...

04 Aug 2025 8-K: Results of Operations and Financial Condition

-CASGEVY®momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth-

26 Jun 2025 8-K: Other Events

On June 26, 2025, CRISPR Therapeutics AG (the “Company”) announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310™, targeting ANGPTL3, as well as continued progress on CTX320™, targeting the...

09 Jun 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

(Translation; in case of controversy the German text shall prevail)

19 May 2025 8-K: Entry into a Material Definitive Agreement; Other Events

[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential.

06 May 2025 8-K: Results of Operations and Financial Condition

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; pres...

26 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

ZUG, Switzerland and BOSTON, March 26, 2025 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer...

11 Feb 2025 8-K: Results of Operations and Financial Condition

-2025 is poised to be a catalyst-rich year with key updates across several programs-

05 Nov 2024 8-K: Results of Operations and Financial Condition

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada-

05 Aug 2024 8-K: Results of Operations and Financial Condition

-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July-

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support